Science, the Economy and the Race to Recovery
Join the FT for a series of events examining the world’s new economic reality in light of Covid-19 and major global political and social change. Over the past year, the FT has been leading the conversation around a new agenda of responsible capitalism during a time of crisis. This series of events adds another dimension to the debate, inviting readers to hear directly from FT journalists on important global issues. This discussion examines the future of the pharma industry, and what a successful vaccine will mean for the economy and markets. Our journalists, US markets reporter, Colby Smith and US pharma and biotech correspondent, Hannah Kuchler, will consider what’s next in the race for a vaccine, the credibility of market moves on scientific trials, and what could happen if these fail.
KEY TALKING POINTS
Are market moves on scientific studies about drugs and vaccines justified? |
What would a successful vaccine mean for the economy and the market? |
|
What could happen if a vaccine fails? |
How could government investment in Covid-19 vaccines change the pharma industry in the long term? |
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice